EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Medical and advanced heart failure therapies in Türkiye

Sanem Nalbantgil iD, Emre Demir iD, Ahmet Çelik iD, İnci Tuğçe Çöllüoğlu iD, Naim Ata iD, Mehmet Birhan Yilmaz iD, Anıl Şahin iD, Dilek Ural iD, Mustafa Mahir Ülgü iD, Emine Arzu Kanik iD, Lale Dinç Asarcikli iD, Yüksel Çavuşoğlu iD und 2 weitere

Turkish Journal of Medical Sciences · 01.01.2024 · 54 (7) · 1470-1477

DOI: 10.55730/1300-0144.5933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2024. Verfasst von Sanem Nalbantgil und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Faculty of Medicine, Ege University, İzmir, Turkiye. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Effective management of heart failure involves evidence-based use of multiple medications and their combinations. Furthermore, dosage escalation of the recommended medications is advised. In cases of advanced heart failure, long-term mechanical assistance devices or heart transplantation surgery may be necessary. The socio-economic situation creates unequal chances for people to access these treatments.The study aimed to analyze and compare medical and advanced heart failure treatments recommended by guidelines across various regions in Türkiye.Materials and methods: About 85 million citizen medical treatment records were utilized between January 1, 2016, and December 31, 2022. Medical and heart replacement treatment opportunities used in heart failure in Türkiye were evaluated in the general population and different geographical regions.

Results

According to this study, beta-blockers were the most commonly prescribed medication for heart failure in Türkiye. This was followed by angiotensin-converting enzyme inhibitors (ACEi) at 44% and mineralocorticoid receptor antagonists (MRA) at 38.9%. However, only 0.6% of patients used angiotensin receptor blocker-neprilysin inhibitors (ARNI). Despite the high incidence of diabetes mellitus among heart failure patients, only 11% used sodium-glucose cotransporter two inhibitors (SGLT-2i). The study also found that using an Implantable Cardioverter Defibrillator (ICD) was 0.8%, and Cardiac Resynchronization Therapy (CRT) was 0.3% among all intracardiac device treatments. Heart replacement therapies, cardiac transplantation surgery, and long-term left ventricle-assisted device (LVAD) surgery had very low rates.

Conclusion

The use of guideline-directed medical therapy is not optimal in Türkiye. Also, it differs within different geographical regions. It is a fact that heart transplant or LVAD surgery, CRT, and ICD implantation rates in Türkiye are significantly lower than in developed countries, regardless of geographical regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansHeart TransplantationAdrenergic beta-AntagonistsMaleFemaleDefibrillators, ImplantableAngiotensin-Converting Enzyme InhibitorsHeart-Assist DevicesMineralocorticoid Receptor AntagonistsMiddle Aged

Stichwörter der Autor:innen

Device therapyheart failuremedical therapynationwide study

Substanzen

Adrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Faculty of Medicine, Ege University, İzmir, Turkiye.
  • Department of Cardiology, Faculty of Medicine, Mersin University, Mersin, Turkiye.
  • Department of Cardiology, Faculty of Medicine, Karabük University, Karabük, Turkiye.
  • General Directorate of the Health Information Systems, Ministry of Health, Ankara, Turkiye.
  • Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye.
  • Department of Cardiology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkiye.

ORCID-Profile: Sanem Nalbantgil, Emre Demir, Ahmet Çelik, İnci Tuğçe Çöllüoğlu, Naim Ata, Mehmet Birhan Yilmaz, Anıl Şahin, Dilek Ural, Mustafa Mahir Ülgü, Emine Arzu Kanik, Lale Dinç Asarcikli, Yüksel Çavuşoğlu, Selda Murat, Şuayip Birinci

Zitieren

APA

Nalbantgil, S., Demir, E., Çelik, A., Çöllüoğlu, İ. T., Ata, N., Yilmaz, M. B., Şahin, A., Ural, D., Ülgü, M. M., Kanik, E. A., Asarcikli, L. D., Çavuşoğlu, Y., Murat, S., & Birinci, Ş. (2024). Medical and advanced heart failure therapies in Türkiye. Turkish Journal of Medical Sciences, 54(7), 1470-1477. https://doi.org/10.55730/1300-0144.5933

Vancouver

Nalbantgil S, Demir E, Çelik A, Çöllüoğlu İT, Ata N, Yilmaz MB, et al. Medical and advanced heart failure therapies in Türkiye. Turkish Journal of Medical Sciences. 2024;54(7):1470-1477. doi:10.55730/1300-0144.5933

BibTeX
@article{Nalbantgil2024,
  author = {Nalbantgil, Sanem and Demir, Emre and Çelik, Ahmet and Çöllüoğlu, İnci Tuğçe and Ata, Naim and Yilmaz, Mehmet Birhan and Şahin, Anıl and Ural, Dilek and Ülgü, Mustafa Mahir and Kanik, Emine Arzu and Asarcikli, Lale Dinç and Çavuşoğlu, Yüksel and Murat, Selda and Birinci, Şuayip},
  title = {Medical and advanced heart failure therapies in Türkiye},
  journal = {Turkish Journal of Medical Sciences},
  year = {2024},
  volume = {54},
  number = {7},
  pages = {1470--1477},
  doi = {10.55730/1300-0144.5933}
}
Kostenlos starten →